nach oben

Erschienen in:

04.12.2019 | Review

Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review

verfasst von: Tahoora Mousavi, Sogol Sattari Saravi, Reza Valadan, Mohammad Reza Haghshenas, Alireza Rafiei, Hamed Jafarpour, Amir Shamshirian

Erschienen in: Archives of Virology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Human papillomavirus (HPV) causes cervical carcinoma, which and is the third most common cancer, accounting for 275,000 deaths annually worldwide. Adjuvants have a key role in promotion of vaccine efficacy; therefore, using prophylactic and therapeutic vaccines combined with adjuvant could be of great benefit in prevention and treatment of cervical cancer. There are different types of adjuvants, including MF59^TM adjuvants, RNA-based, JY (interleukin2/chitosan), cholera toxin (CT), heat-labile enterotoxin (LT), Freund’s adjuvant, alum, SA-4-1BBL, λ-carrageenan (λ-CGN), heat shock proteins (HSPs), juzen-taiho-to (JTT) and hochu-ekki-to (HET), ISCOM and ISCOMATRIX™, very small size proteoliposomes (VSSPs), granulocyte macrophage colony-stimulating factor (GM-CSF), and Toll-like receptors (TLRs). Adjuvants have various functions, especially in therapeutic vaccines, and they lead to an increase in cytotoxic T lymphocytes (CTLs), so they are important in the design of vaccines. Here, we review the currently used adjuvants and their combinations with HPV protein vaccines in order to introduce an appropriate adjuvant for HPV vaccines.

Nur mit Berechtigung zugänglich

Bosch F, Lorincz A, Munoz N, Meijer C, Shah K (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55(4):244–265PubMedPubMedCentral

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386PubMed

Haghshenas MR, Mousavi T, Kheradmand M, Afshari M, Moosazadeh M (2017) Efficacy of human papillomavirus l1 protein vaccines (cervarix and gardasil) in reducing the risk of cervical intraepithelial neoplasia: a meta-analysis. Int J Prev Med 8:14

Amarakoon AGU, Daulagala S, Fathima F (2016) An overview of human papilloma virus. World Sci News 3(53):275–308

Yang A, Farmer E, Wu T, Hung C-F (2016) Perspectives for therapeutic HPV vaccine development. J Biomed Sci 23(1):75PubMedPubMedCentral

Haghshenas MR, Mousavi T, Moosazadeh M, Afshari M (2016) Human papillomavirus and breast cancer in Iran: a meta-analysis. Iran J Basic Med Sci 19(3):231PubMedPubMedCentral

Niazy F, Rostami K, Motabar AR (2015) Giant condyloma acuminatum of vulva frustrating treatment challenge. World J Plast Surg 4(2):159PubMedPubMedCentral

Landy R, Windridge P, Gillman MS, Sasieni PD (2018) What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. Int J Cancer 142(4):709–718PubMed

Moscicki A-B (2007) HPV infections in adolescents. Dis Mark 23(4):229–234

10.

Wang HL, Xu H, Lu WH, Zhu L, Yu YH, Hong FZ (2014) In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer. Arch Gynecol Obstet 289(1):155–162PubMed

11.

Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D et al (2010) Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res 36(1):123–132PubMed

12.

Bosch FX, de Sanjosé S (2007) The epidemiology of human papillomavirus infection and cervical cancer. Dis Mark 23(4):213–227

13.

Cui Z, Huang L (2005) Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother 54(12):1180–1190PubMed

14.

Frazer IH (2010) Cervical cancer vaccine development. Sex Health 7(3):230–234PubMed

15.

Gherardi RK, Aouizerate J, Cadusseau J, Yara S, Authier FJ (2016) Aluminum adjuvants of vaccines injected into the muscle: normal fate, pathology and associated disease. Morphologie bulletin de l’Association des anatomistes 100(329):85–94PubMed

16.

Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J et al (2015) A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372(8):711–723PubMed

17.

de Cassan SC, Forbes EK, Douglas AD, Milicic A, Singh B, Gupta P et al (2011) The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J Immunol (Baltimore, Md: 1950) 187(5):2602–2616

18.

Goodman AL, Draper SJ (2010) Blood-stage malaria vaccines—recent progress and future challenges. Ann Trop Med Parasitol 104(3):189–211PubMed

19.

Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Adjuvants and autoimmunity. Lupus 18(13):1217–1225PubMed

20.

Gellin BG, Salisbury DM (2015) Communicating the role and value of vaccine adjuvants. Vaccine 33(Suppl 2):B44–B46PubMed

21.

Seder R, Reed SG, O’Hagan D, Malyala P, D’Oro U, Laera D et al (2015) Gaps in knowledge and prospects for research of adjuvanted vaccines. Vaccine 33(Suppl 2):B40–B43PubMed

22.

Kashiwagi S, Brauns T, Gelfand J, Poznansky MC (2014) Laser vaccine adjuvants. History, progress, and potential. Hum Vaccines Immunother 10(7):1892–1907

23.

Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med 4(10):e297PubMedPubMedCentral

24.

Li Y, Xu XL, Zhao D, Pan LN, Huang CW, Guo LJ et al (2015) TLR 3 ligand poly IC attenuates reactive astrogliosis and improves recovery of rats after focal cerebral ischemia. CNS Neurosci Ther 21(11):905–913PubMedPubMedCentral

25.

Wick DA, Martin SD, Nelson BH, Webb JR (2011) Profound CD8 + T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly (I: C). Vaccine 29(5):984–993PubMed

26.

Yang X, Cheng Y, Li C (2017) The role of TLRs in cervical cancer with HPV infection: a review. Signal Transduct Target Ther 2:17055PubMedPubMedCentral

27.

Khong H, Overwijk WW (2016) Adjuvants for peptide-based cancer vaccines. J Immunother Cancer 4(1):56PubMedPubMedCentral

28.

Bates JT, Uematsu S, Akira S, Mizel SB (2009) Direct stimulation of tlr5 +/+ CD11c + cells is necessary for the adjuvant activity of flagellin. J Immunol 182(12):7539–7547PubMed

29.

Cui B, Liu X, Fang Y, Zhou P, Zhang Y, Wang Y (2018) Flagellin as a vaccine adjuvant. Expert Rev Vaccines 17(4):335–349PubMed

30.

Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF (2008) The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13(8):859–875PubMed

31.

Dockrell D, Kinghorn G (2001) Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 48(6):751–755PubMed

32.

Levy O, Goriely S, Kollmann TR (2013) Immune response to vaccine adjuvants during the first year of life. Vaccine 31(21):2500–2505PubMed

33.

Arany I, Tyring SK, Stanley MA, Tomai MA, Miller RL, Smith MH et al (1999) Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antivir Res 43(1):55–63PubMed

34.

Khong H, Overwijk WW (2016) Adjuvants for peptide-based cancer vaccines. J Immunother Cancer 4:56PubMedPubMedCentral

35.

Hartoonian C, Ebtekar M, Soleimanjahi H, Karami A, Mahdavi M, Rastgoo N et al (2009) Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine. Cytokine 46(1):43–50PubMed

36.

Tang J, Yin R, Tian Y, Huang Z, Shi J, Fu X et al (2012) A novel self-assembled nanoparticle vaccine with HIV-1 Tat49-57/HPV16 E749-57 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice. Vaccine 30(6):1071–1082PubMed

37.

Venier C, Guthmann M, Fernandez L, Fainboim L (2007) Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant. Clin Exp Immunol 147(2):379–388PubMedPubMedCentral

38.

Torréns I, Mendoza O, Batte A, Reyes O, Fernández LE, Mesa C et al (2005) Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine 23(50):5768–5774PubMed

39.

Sun H-X, Xie Y, Ye Y-P (2009) ISCOMs and ISCOMATRIX™. Vaccine 27(33):4388–4401PubMed

40.

Sanders MT, Brown LE, Deliyannis G, Pearse MJ (2005) ISCOMTM-based vaccines: the second decade. Immunol Cell Biol 83(2):119–128PubMed

41.

Manfredi F, di Bonito P, Ridolfi B, Anticoli S, Arenaccio C, Chiozzini C et al (2016) The CD8⁺ T cell-mediated immunity induced by HPV-E6 uploaded in engineered exosomes is improved by ISCOMATRIXTM adjuvant. Vaccines 4(4):42PubMedCentral

42.

Peng S, Wang JW, Karanam B, Wang C, Huh WK, Alvarez RD et al (2015) Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. PLoS One 10(1):e116389PubMedPubMedCentral

43.

Tsuchiya M, Kono H, Matsuda M, Fujii H, Rusyn I (2008) Protective effect of Juzen-taiho-to on hepatocarcinogenesis is mediated through the inhibition of Kupffer cell-induced oxidative stress. Int J Cancer 123(11):2503–2511PubMedPubMedCentral

44.

Cho J, Sato N, Kikuchi K (1991) Prophylactic anti-tumor effect of Hochu-ekki-to (TJ41) by enhancing natural killer cell activity. In vivo (Athens, Greece) 5(4):389–391

45.

Taguchi A, Kawana K, Yokoyama T, Adachi K, Yamashita A, Tomio K et al (2012) Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner. Vaccine 30(36):5368–5372PubMed

46.

Lin K, Roosinovich E, Ma B, Hung C-F, Wu T-C (2010) Therapeutic HPV DNA vaccines. Immunol Res 47(1–3):86–112PubMedPubMedCentral

47.

Mohit E, Bolhassani A, Zahedifard F, Taslimi Y, Rafati S (2012) The Contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL/6 mouse model. Scand J Immunol 75(1):27–37PubMed

48.

Zong J, Wang C, Liu B, Liu M, Cao Y, Sun X et al (2013) Human hsp70 and HPV16 oE7 fusion protein vaccine induces an effective antitumor efficacy. Oncol Rep 30(1):407–412PubMed

49.

Weiner ML (2014) Food additive carrageenan: part II: a critical review of carrageenan in vivo safety studies. Crit Rev Toxicol 44(3):244–269PubMed

50.

Bhattacharyya S, Liu H, Zhang Z, Jam M, Dudeja PK, Michel G et al (2010) Carrageenan-induced innate immune response is modified by enzymes that hydrolyze distinct galactosidic bonds. J Nutr Biochem 21(10):906–913PubMed

51.

Li J, Aipire A, Li J, Zhu H, Wang Y, Guo W et al (2017) λ-Carrageenan improves the antitumor effect of dendritic cell based vaccine. Oncotarget 8(18):29996PubMedPubMedCentral

52.

Sharma RK, Yolcu ES, Shirwan H (2014) SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines. Expert Rev Vaccines 13(3):387–398PubMedPubMedCentral

53.

Srivastava AK, Dinc G, Sharma RK, Yolcu ES, Zhao H, Shirwan H (2014) SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Res 74(22):6441–6451PubMedPubMedCentral

54.

Koutsky LA, Harper DM (2006) Current findings from prophylactic HPV vaccine trials. Vaccine 24:S114–S121

55.

Sharma C, Dey B, Wahiduzzaman M, Singh N (2012) Human papillomavirus 16 L1–E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer. Vaccine 30(36):5417–5424PubMed

56.

Wu W-H, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA (2015) Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. Virol J 12(1):140PubMedPubMedCentral

57.

Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH (2007) CD8 + CTL priming by exact peptide epitopes in incomplete Freund’s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 179(8):5033–5040PubMed

58.

Badaracco G, Venuti A (2007) Human papillomavirus therapeutic vaccines in head and neck tumors. Expert Rev Anticancer Ther 7(5):753–766PubMed

59.

Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, Brown RG et al (2006) Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 24(24):5235–5244PubMed

60.

Monroy-García A, Gómez-Lim MA, Weiss-Steider B, Hernández-Montes J, Huerta-Yepez S, Rangel-Santiago JF et al (2014) Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model. Arch Virol 159(2):291–305PubMed

61.

Ryan EJ, Daly LM, Mills KH (2001) Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol 19(8):293–304PubMed

62.

Xu Y, Zhang H, Xu X (2008) Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles. FEMS Immunol Med Microbiol 52(1):99–109PubMed

63.

Da Hora VP, Conceição FR, Dellagostin OA, Doolan DL (2011) Non-toxic derivatives of LT as potent adjuvants. Vaccine 29(8):1538–1544PubMed

64.

Brunner R, Jensen-Jarolim E, Pali-Schöll I (2010) The ABC of clinical and experimental adjuvants—a brief overview. Immunol Lett 128(1):29–35PubMed

65.

Jee J, Bonnegarde-Bernard A, Duverger A, Iwakura Y, Cormet-Boyaka E, Martin TL et al (2015) Neutrophils negatively regulate induction of mucosal IgA responses after sublingual immunization. Mucosal Immunol 8(4):735PubMedPubMedCentral

66.

Manuri PR, Nehete B, Nehete PN, Reisenauer R, Wardell S, Courtney AN et al (2007) Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 25(17):3302–3310PubMedPubMedCentral

67.

Xu J, Li S, Wang X, Liu J, Shan P, Zhou Y et al (2018) Systemic and mucosal humoral immune responses induced by the JY-adjuvanted nasal spray H7N9 vaccine in mice. Emerg Microbes Infect 7(1):1–9

68.

Hua Y, Jiao Y-Y, Ma Y, Peng X-L, Fu Y-H, Zheng Y-P et al (2016) DNA vaccine encoding central conserved region of G protein induces Th1 predominant immune response and protection from RSV infection in mice. Immunol Lett 179:95–101PubMed

69.

Tafaghodi M, Saluja V, Kersten GF, Kraan H, Slütter B, Amorij J-P et al (2012) Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: impact of formulation on physicochemical and immunological characteristics. Vaccine 30(36):5341–5348PubMed

70.

Ma F, Zhang Q, Zheng L (2015) Interleukin/chitosan (JY) adjuvant enhances the mucosal immunity of human papillomavirus 16 L1 virus-like particles in mice. Biotechnol Lett 37(4):773–777PubMed

71.

Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P et al (2015) A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Int J Cancer 137(2):372–384PubMed

72.

Lundstrom K (2018) Latest development on RNA-based drugs and vaccines. Future Sci OA 4(5):FSO300PubMedPubMedCentral

73.

Onomoto K, Jogi M, Yoo JS, Narita R, Morimoto S, Takemura A et al (2012) Critical role of an antiviral stress granule containing RIG-I and PKR in viral detection and innate immunity. PLoS One 7(8):e43031PubMedPubMedCentral

74.

Circelli L, Petrizzo A, Tagliamonte M, Heidenreich R, Tornesello ML, Buonaguro FM et al (2017) Immunological effects of a novel RNA-based adjuvant in liver cancer patients. Cancer Immunol Immunother 66(1):103–112PubMed

75.

Sahly HE (2010) MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines 9(10):1135–1141PubMed

76.

Zhu X, Tommasino M, Vousden K, Sadovnikava E, Rappuoli R, Crawford L et al (1995) Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice. Scand J Immunol 42(5):557–563PubMed

77.

Aguilar J, Rodriguez E (2007) Vaccine adjuvants revisited. Vaccine 25(19):3752–3762PubMed

78.

Lee SE, Hong SH, Verma V, Lee YS, Duong T-MN, Jeong K et al (2016) Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer. Oncoimmunology 5(2):e1081328PubMed

79.

Kuroda E, Ishii KJ, Uematsu S, Ohata K, Coban C, Akira S et al (2011) Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 34(4):514–526PubMed

80.

Ackerman AL, Cresswell P (2004) Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 5(7):678PubMed

81.

Spickler AR, Roth JA (2003) Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med 17(3):273–281PubMed

82.

Combita A-L, Touzé A, Bousarghin L, Christensen ND, Coursaget P (2002) Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76(13):6480–6486PubMedPubMedCentral

83.

White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim S-J, Hewitt LA et al (1999) Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 73(6):4882–4889PubMedPubMedCentral

84.

Fukui A, Matsueda S, Kawano K, Tsuda N, Komatsu N, Shichijo S et al (2012) Identification of B cell epitopes reactive to human papillomavirus type-16L1-derived peptides. Virol J 9:199PubMedPubMedCentral

85.

Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA (2015) Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. Virol J 12:140PubMedPubMedCentral

86.

Senger T, Schädlich L, Textor S, Klein C, Michael KM, Buck CB et al (2010) Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs. Vaccine 28(6):1583–1593PubMed

87.

Tobery TW, Smith JF, Kuklin N, Skulsky D, Ackerson C, Huang L et al (2003) Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. Vaccine 21(13):1539–1547PubMed

88.

Seitz H, Ribeiro-Müller L, Canali E, Bolchi A, Tommasino M, Ottonello S et al (2015) Robust in vitro and in vivo neutralization against multiple high-risk HPV types induced by a thermostable thioredoxin-L2 vaccine. Cancer Prev Res 8(10):932–941

89.

Hassett KJ, Meinerz NM, Semmelmann F, Cousins MC, Garcea RL, Randolph TW (2015) Development of a highly thermostable, adjuvanted human papillomavirus vaccine. Eur J Pharm Biopharm 94:220–228PubMedPubMedCentral

90.

De Bruijn ML, Greenstone HL, Vermeulen H, Melief CJ, Lowy DR, Schiller JT et al (1998) L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250(2):371–376PubMed

91.

Xu W-X, Wang J, Tang H-P, He Y-P, Zhu Q-X, Gupta SK et al (2016) Epitomics: IgG-epitome decoding of E6, E7 and L1 proteins from oncogenic human papillomavirus type 58. Sci Rep 6:34686PubMedPubMedCentral

92.

Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, Christensen ND et al (2007) A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 25(11):2001–2010PubMed

93.

Hagensee ME, Carter JJ, Wipf GC, Galloway DA (1995) Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies. Virology 206(1):174–182PubMed

94.

Qin Y, Wang X, Cui H, Cheung Y, Hu M, Zhu S et al (2005) Human papillomavirus type 16 E7 peptide38–61 linked with an immunoglobulin G fragment provides protective immunity in mice. Gynecol Oncol 96(2):475–483PubMed

95.

Korsholm KS, Hansen J, Karlsen K, Filskov J, Mikkelsen M, Lindenstrøm T et al (2014) Induction of CD8⁺ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant. Vaccine 32(31):3927–3935PubMed

96.

Greer CE, Petracca R, Buonamassa DT, Di Tommaso A, Gervase B, Reeve RL et al (2000) The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles. Vaccine 19(9–10):1008–1012PubMed

97.

Liu C, Chu X, Sun P, Feng X, Huang W, Liu H, Ma Y (2018) Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model. Hum Vaccines Immunother 7(3):931–940

98.

Freyschmidt E-J, Alonso A, Hartmann G, Gissmann L (2004) Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol. Antivir Ther 9:479–490PubMed

99.

Ye GW, Park J-B, Park Y-J, Choi YS, Sin J-I (2007) Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity. Mol Ther 15(8):1564–1570PubMed

100.

Welters MJ, Filippov DV, van den Eeden SJ, Franken KL, Nouta J, Valentijn ARP et al (2004) Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. Vaccine 23(3):305–311PubMed

101.

Kim TG, Kim CH, Won EH, Bae SM, Ahn WS, Park JB et al (2004) CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology 112(1):117–125PubMedPubMedCentral

102.

Reiniš M, Šímová J, Bubeník J (2006) Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and-proficient HPV16-associated tumours. Int J Cancer 118(7):1836–1842PubMed

103.

Song Y-C, Cheng H-Y, Leng C-H, Chiang S-K, Lin C-W, Chong P et al (2014) A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8⁺ T-cell-mediated anti-tumor immunity. J Control Release 173:158–165PubMed

104.

Song L, Yang M-C, Knoff J, Wu T-C, Hung C-F (2014) Cancer immunotherapy employing an innovative strategy to enhance CD4⁺ T cell help in the tumor microenvironment. PLoS One 9(12):e115711PubMedPubMedCentral

105.

Liao S, Zhang W, Hu X, Wang W, Deng D, Wang H et al (2015) A novel “priming-boosting” strategy for immune interventions in cervical cancer. Mol Immunol 64(2):295–305PubMed

106.

Domingos-Pereira S, Decrausaz L, Derré L, Bobst M, Romero P, Schiller JT et al (2013) Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol 6(2):393PubMed

107.

Gomes AC, Flace A, Saudan P, Zabel F, Cabral-Miranda G, Turabi AE et al (2017) Adjusted particle size eliminates the need of linkage of antigen and adjuvants for appropriated T cell responses in virus-like particle-based vaccines. Front Immunol 8:226PubMedPubMedCentral

108.

Kang TH, Monie A, Wu LS-F, Pang X, Hung C-F, Wu T-C (2011) Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection. Vaccine 29(5):1082–1089PubMed

109.

Pokorná D, Poláková I, Kindlová M, Dušková M, Ludvíková V, Gabriel P et al (2009) Vaccination with human papillomavirus type 16-derived peptides using a tattoo device. Vaccine 27(27):3519–3529PubMed

110.

Dell K, Koesters R, Gissmann L (2006) Transcutaneous immunization in mice: Induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. Int J Cancer 118(2):364–372PubMed

111.

Chandy AG, Nurkkala M, Josefsson A, Eriksson K (2007) Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours. Vaccine 25(32):6037–6046PubMed

112.

Mao X, Chen X, Zhang W, Wang J, Liu L, Zhou Q et al (2011) TLR agonists activate HPV11 E7-pulsed DCs to promote a specific T cell response in a murine model. Veterinarni Medicina 56(12):602–611

113.

Nguyen CT, Hong SH, Ung TT, Verma V, Kim SY, Rhee JH et al (2013) Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model. Clin Exp Vaccine Res 2(2):128–134PubMedPubMedCentral

114.

Ren F, Xu Y, Mao L, Ou R, Ding Z, Zhang X et al (2010) Heat shock protein 110 improves the anti-tumor effects of the cytotoxic T lymphocyte epitope E7 in mice. Cancer Biol Ther 9(2):134–141PubMed

115.

Liu D-W, Tsao Y-P, Kung JT, Ding Y-A, Sytwu H-K, Xiao X et al (2000) Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 74(6):2888–2894PubMedPubMedCentral

116.

Liu B, Ye D, Song X, Zhao X, Yi L, Song J et al (2008) A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Vaccine 26(10):1387–1396PubMed

117.

Xu Y, Zhang H, Xu X (2007) Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles. FEMS Immunol Med Microbiol 52(1):99–109PubMed

118.

Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli-Haefliger D (1998) Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 72(10):8220–8229PubMedPubMedCentral

119.

Çuburu N, Kweon M-N, Hervouet C, Cha H-R, Pang Y-YS, Holmgren J et al (2009) Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 183(12):7851–7859PubMed

120.

Malliaros J, Quinn C, Arnold FH, Pearse MJ, Drane DP, Stewart TJ et al (2004) Association of antigens to ISCOMATRIX™ adjuvant using metal chelation leads to improved CTL responses. Vaccine 22(29–30):3968–3975PubMed

121.

Tarpey I, Stacey SN, McIndoe A, Davies DH (1996) Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs). Vaccine 14(3):230–236PubMed

122.

Franconi R, Di Bonito P, Dibello F, Accardi L, Muller A, Cirilli A et al (2002) Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res 62(13):3654–3658PubMed

123.

Massa S, Franconi R, Brandi R, Muller A, Mett V, Yusibov V et al (2007) Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine 25(16):3018–3021PubMed

124.

Karanam B, Gambhira R, Peng S, Jagu S, Kim D-J, Ketner GW et al (2009) Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 27(7):1040–1049PubMed

125.

Esquerré M, Bouillette-Marussig M, Goubier A, Momot M, Gonindard C, Keller H et al (2017) GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8⁺ T cell responses leading to tumor regression. PLoS One 12(3):e0174038PubMedPubMedCentral

126.

Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky R-H, Madireddi S et al (2010) SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. Vaccine 28(36):5794–5802PubMedPubMedCentral

Titel: Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review
verfasst von: Tahoora Mousavi
Sogol Sattari Saravi
Reza Valadan
Mohammad Reza Haghshenas
Alireza Rafiei
Hamed Jafarpour
Amir Shamshirian
Publikationsdatum: 04.12.2019
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 2/2020
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-019-04479-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Identification of rotavirus A strains in small ruminants: first detection of G8P[1] genotypes in sheep in Turkey

Complete genome sequence of a novel polerovirus in Ornithogalum thyrsoides from South Africa

Distinctive features of bovine alphaherpesvirus types 1 and 5 and the virus-host interactions that might influence clinical outcomes

Characterization of an infectious clone of pepper ringspot virus and its use as a viral vector

Genetic characterization of a novel recombinant echovirus 30 strain causing a regional epidemic of aseptic meningitis in Hokkaido, Japan, 2017

A novel picornavirus identified in wild Macaca mulatta in China

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin